Columns

When you’re a caregiver to someone with Angelman syndrome, making time for yourself seems like an impossibility. However, I consider this necessity an important part of my caregiver responsibilities. After all, if I don’t look out for my own well-being, I’ll burn out. And that will make the job…

I used to think that my 13-year-old Angel, Juliana, screamed a lot because she lacked understanding. There might be some truth to that, but something else is at play. Many of her outbursts are good old-fashioned tantrums that she’s performing to get her way. But I’ve started…

“Does she understand?” a friend asked me as Juliana watched a show on her iPad. It’s not uncommon for people to ask me if Juliana, my 13-year-old daughter with Angelman syndrome, understands what’s going on around her. Comprehension is a tricky topic when you’re dealing with a neurogenic…

A houseguest once passed her finger along a shelf in my house and asked, “Don’t you dust?” I was slightly offended, but didn’t overreact. I just briefly explained that I was a little busy. There are a lot of activities in our house that must be completed to ensure the…

Self-care has been an important part of the quality of support I provide for my 13-year-old Angel, Juliana. As the years add up for each of us, however, the word has taken on a new meaning. Regretfully, I’ve let a few things slip with my health over…

Communication is one of the skills I am most grateful for when I think about how my 13-year-old Angel, Juliana, is growing and changing. The other day, I thought about how far she has come since she was first introduced to the iPad. Our device was gifted by…

I’m not shocked when my 13-year-old Angel, Juliana, masters a skill we’ve worked on for a while. That’s because I know she learns best through repetition. But a few weeks ago, Juliana started snapping her fingers out of the blue. Her snaps aren’t hard and polished, but there’s no…

I was disappointed to read the news recently about new data from a Phase 3 clinical trial of an investigational treatment for Angelman syndrome called OV101 (gaboxadol). Developed by Ovid Therapeutics, the experimental treatment did not appear to combat the complexities brought on by Angelman.